CytRx Puts Its Cancer Pipeline to the Test
All told, the Los Angeles-based company could have six to eight trials running simultaneously in the coming months.
All told, the Los Angeles-based company could have six to eight trials running simultaneously in the coming months.
CytRx, a biopharmaceutical research and development company, has announced plans to initiate a Phase II clinical trial for its drug candidate INNO-206 to treat patients who suffer from advanced, treatment-resistant soft tissue sarcoma.
Copyright © 2024 | WordPress Theme by MH Themes